Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences’ Breakthrough Research [Benzinga]
Wednesday, September 25, 2024 1 min read
Key Takeaway: Enveric Biosciences has showcased its lead compound, EB-003, at the 7th Neuropsychiatric Drug Summit. This non-hallucinogenic DMT analog demonstrated promising results in preclinical models for treating anxiety and depression. The research highlights the potential of EB-003 as a safer alternative in psychedelic treatments.
Price reaction · baseline $85.518 (2024-09-24 close) · hit pre-market · 3 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+7.1%
day 1
+0.9%
day 3
-0.2%
Market Sentiment Analysis
POSITIVE FACTORS
EB-003 shows beneficial outcomes in preclinical models.
The compound is non-hallucinogenic, making it a safer option.
Research presented at a reputable summit enhances credibility.
Full Press Release Details
Psychedelics biotech company Enveric Biosciences has presented research highlighting its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit showing beneficial outcomes in preclinical models of anxiety and depression.
EB-003 is a neuropathogenic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate.
Full Article >>
Frequently Asked Questions
What is EB-003?
EB-003 is a non-hallucinogenic analog of DMT developed by Enveric Biosciences.
What conditions does EB-003 target?
EB-003 is aimed at treating anxiety and depression.
Where was the research on EB-003 presented?
The research was presented at the 7th Neuropsychiatric Drug Summit.